Loading…

S129: TAKEAIM LEUKEMIA‐ A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA‐4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS

Saved in:

Bibliographic Details
Published in:	HemaSphere 2022-06, Vol.6 (Suppl), p.30-31
Main Authors:	Garcia‐Manero, G., Winer, E. S., DeAngelo, D. J., Tarantolo, S., Sallman, D. A., Dugan, J., Groepper, S., Giagounidis, A., Götze, K., Metzeler, K. H., Li, C.‐C., Zhou, L., Martinez, E., Lane, M., Roemeling, R., Bohme, M., Kubasch, A. S., Verma, A., Platzbecker, U.
Format:	Article
Language:	English
Subjects:	Oral Sessions
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!